Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [(177)Lu]Lu-OPS201 Compared to the Agonist [(177)Lu]Lu-DOTA-TATE

Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST(2)) peptide agonist [(177)Lu]Lu-DOTA-TATE is effective and well-established. Recent studies suggest improved therapeutic efficacy using the SST(2) peptide antagonist [(177)Lu]Lu-OPS201. However, little is...

Descripción completa

Detalles Bibliográficos
Autores principales: Mansi, Rosalba, Plas, Pascale, Vauquelin, Georges, Fani, Melpomeni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706879/
https://www.ncbi.nlm.nih.gov/pubmed/34959665
http://dx.doi.org/10.3390/ph14121265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706879/
https://www.ncbi.nlm.nih.gov/pubmed/34959665
http://dx.doi.org/10.3390/ph14121265

Ejemplares similares